US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

19.14

-0.2098-1.08%

Post-market: 19.140.00000.00%19:30 EDT

Volume:127.96K

Turnover:2.44M

Market Cap:112.91M

PE:- -

High:19.20

Open:19.04

Low:18.87

Close:19.35

52wk High:21.50

52wk Low:14.38

Shares:5.90M

Float Shares:5.90M

Volume Ratio:2.99

T/O Rate:2.17%

Dividend:0.71

Dividend Rate:3.73%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Major Drugmakers Turn to China for Licensing Deals

Wuxi Biologics (Cayman) Stock Slides 2.7% in Hong Kong

Akeso (SEHK:9926) Could Be 31% Undervalued As Phase III Trial Hits Key Goals

Simply Wall St.

CSPC Pharmaceutical Group (SEHK:1093) Could Be 26% Undervalued Following Three Phase III Updates

Simply Wall St.

CSPC Reports Blood Sugar Reduction in Phase III Diabetes Study

MT Newswires Live

What IBI3003 Trial Progress Means For Innovent Biologics Stock

Simply Wall St.

Major Drugmakers Turn to China for Licensing Deals

CSPC Pharmaceutical (01093) Reveals Positive Phase III Results for Edaglutide Alfa Injection Combined with Metformin in Chinese Adults with Type 2 Diabetes at EASD 2026

Should Phase III Cancer Trial Win Require Action From Akeso Stock Investors?

Simply Wall St.

CSPC Pharmaceutical Group Stock Rallies 6.3% in Hong Kong, Outperforms Competitors

Wuxi Biologics (Cayman) Stock Rises 4.8% in Hong Kong

Goldman Sachs: Asian CDMOs Enter a Structural Growth Cycle, with Peptides, ADCs, Oligonucleotides, and AIDD as New Engines

Daiwa: Akeso's Global Partner Summit Secures AstraZeneca Investment, Boosting Ivonescimab's Global Peak Sales Potential

Nomura Assigns HK$138.29 Target Price and "Buy" Rating to Akeso

AI Drug Discovery Sector Heats Up: ChinaAMC Hang Seng Biotech (03069) Rises Over 4% Intraday, ChinaAMC Innovative Drugs (03525) Gains Over 3% in Afternoon Session

Hong Kong Pharma Stocks Defy Market Slump as AI Drug Discovery Leads; GenScript Surges Over 9% to New High, Hang Seng Healthcare ETF Huabao (159137) Underlying Index Rises Over 2%

CSPC Pharma Shares Rise Nearly 6% on String of R&D Updates Spanning mRNA Cancer Vaccines and Recombinant Protein Vaccines

Behind the Surge in BD Deals: Decoding the Differentiated Advantages of China's Innovative Drugs

CSPC Hits 5-Week High on US FDA's Nod on Herpes Zoster Vaccine Trial

Hong Kong Stock Connect Innovative Drug Sector Defies Market Downturn as Top Pharmaceutical Firm Enters with US$2 Billion, Akeso Surges 15.54%, Hengrui Pharma Secures US$2.6 Billion BD Deal

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/KURE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KURE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":19.14,"timestamp":1790971200000,"preClose":19.3498,"halted":0,"volume":127957,"hourTrading":{"tag":"盘后","latestPrice":19.14,"preClose":19.14,"latestTime":"19:30 EDT","volume":8,"amount":153.12,"timestamp":1790983803066,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.010842489328054955,"floatShares":5899036,"shares":5899036,"eps":0,"marketStatus":"Market Closed","change":-0.2098,"latestTime":"10-02 16:00:00 EDT","open":19.04,"high":19.2,"low":18.87,"amount":2436278.887525,"amplitude":0.017054,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":19.3498,"sharesOutstanding":4750002,"nav":19.06,"aum":112453199.16,"dividendRate":0.037315,"bidAskSpread":0.008807,"postHourTrading":{"tag":"盘后","latestPrice":19.14,"preClose":19.14,"latestTime":"19:30 EDT","volume":8,"amount":153.12,"timestamp":1790983803066,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.9854503635447447,"impliedVol":0.1722,"impliedVolPercentile":0.3665},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","floatShares":5899036,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.9854503635447447,"shares":5899036,"dividePrice":0.7142,"high":19.2,"amplitude":0.017054,"preClose":19.3498,"low":18.87,"week52Low":14.3797,"pbRate":"--","week52High":21.5,"institutionHeld":0,"latestPrice":19.14,"eps":0,"divideRate":0.037315,"volume":127957,"delay":0,"ttmEps":0,"open":19.04,"prevYearClose":17.04,"prevWeekClose":18.72,"prevMonthClose":19.25,"prevQuarterClose":19.25,"fiveDayClose":18.72,"twentyDayClose":18.91,"sixtyDayClose":16.4655},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KURE\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"KURE","amount":0.714689,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KURE","amount":0.18361,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"},{"date":"2023-12-18","symbol":"KURE","amount":0.112844,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2023-12-20","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-20"},{"market":"US","date":"2022-12-28","symbol":"KURE","amount":0.010399,"defaultRemindTime":1672237800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2022-12-30","payableDate":"2022-12-29","currency":"USD","type":"dividend","dateTimestamp":1672203600000},{"market":"US","date":"2021-12-29","symbol":"KURE","amount":4.053448,"defaultRemindTime":1640788200000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KURE\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-26","recordDate":"2018-12-27","paymentDate":"2018-12-28","value":0.039344,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":0.057325,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.000109,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":4.053448,"currency":"USD"},{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.010399,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KURE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KURE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672715686","title":"Major Drugmakers Turn to China for Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2672715686","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672715686?lang=en_us&edition=fundamental","pubTime":"2026-10-02 17:50","pubTimestamp":1790934645,"startTime":"0","endTime":"0","summary":"FACTBOX-Major drugmakers turn to China for licensing dealsOct 2 (Reuters)-Abogen said on Friday it has signed a licensing deal worth up to $7.8 billion with Swiss drugmaker NovartisNOVN.Sto develop an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nL4N45O0HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225283273.USD","LU0965509010.AUD","LU0823416689.USD","03933","LU1093756325.SGD","LU1718418525.SGD","LU1119994496.HKD","LU1934455194.USD","PPH","IE00BLSP4452.SGD","MHIP","LU2168564149.EUR","LU2211815571.USD","SG9999015952.SGD","LU0472753341.HKD","LU0857590862.USD","LU1328277881.USD","BK1191","LU2746668461.USD","LU0306806265.USD","LU2357627491.SGD","LU2471134952.CNY","LU1366192091.USD","BK0060","LU2023250843.SGD","IE00BJT1NW94.SGD","BK4007","LU1997244956.HKD","SG9999015978.USD","688506","LU1244550221.USD","LU0289961442.SGD","LU2237443895.HKD","SGXZ51526630.SGD","LU0471298694.HKD","LU0306807586.USD","LU0463099449.HKD","LU2461242641.AUD","LU0980610538.SGD","03692","LU0094547139.USD","IE00BJLML261.HKD","SG9999014567.USD","LU0920840948.USD","MEDI","688331","IXJ","LU0265550946.USD","IE00B775H168.HKD","LU0053666078.USD","LU2097828714.EUR","LU0320765992.SGD","LU0795875169.SGD","LU2552382132.HKD","LU1273509221.SGD","BMED","LU0827474353.SGD","IE00BN8TJ469.HKD","TRUH","LU1989772923.USD","NVOX","LU2347655156.SGD","LU0887340254.USD","LU2279689827.SGD","LU2168564065.EUR","ELIS","LU0795875086.SGD","LU1813983027.USD","LU2462157665.USD","FTXH","LU0526926950.USD","LU1989771016.USD","LU1629891620.HKD","LU0122379950.USD","LU0920783379.SGD","NVO","LU2324357040.USD","IE00BZ1G4Q59.USD","LLYZ","IE00BFTCPJ56.SGD","LU2471134879.HKD","LU0289739343.SGD","LU1008478684.HKD","SG9999015945.SGD","LU0957799991.USD","LU2491050154.USD","IE00B42XCP33.USD","SG9999017495.SGD","LU2491049909.HKD","LU2552382215.SGD","LU0289739699.SGD","LU2089984988.USD","IBBQ","LU2362541513.USD","LU0265550359.USD","LU2271345857.HKD","LU2089284900.SGD","LU0868494617.USD","01530","LU2293690249.USD","LU2491050071.SGD","LU0345777147.USD","LU0315179316.USD","LU1116320901.HKD","LU1961090484.USD","LU0575583348.USD","LU2471134796.USD","LU0471298777.SGD","LU1941712348.USD","LLY","IE00BLSP4239.USD","IE00BVYPNW00.USD","LU0868494708.USD","LU1037948541.HKD","ILDR","LU1201861249.SGD","IE00BZ08YT58.USD","LU0234572021.USD","VHT","LU0417516902.SGD","LU0267386448.USD","LU0545562505.USD","ABBV","NVOC","LU0079474960.USD","TMED","LU0726765562.USD","LU2756315664.SGD","LU1244550577.SGD","LU2023250330.USD","CANC","LU2237443622.USD","LU0787776722.HKD","LU2417539215.USD","LU2361044949.HKD","LU2362541273.HKD","LU1255011170.USD","IE00BZ08YR35.GBP","LU0880133367.SGD","LU0417516571.SGD","LU1868836591.USD","LU2097828631.EUR","LU1145028129.USD","LU1571399168.USD","BK4559","LU0149534421.HKD","LU0210536198.USD","LU0171293334.USD","LU0757432116.USD","LU0098860793.USD","IE000F7OJYX1.SGD","LU1670628061.USD","LU0417517546.SGD","LU0820562030.AUD","SG9999014575.USD","LU1655091616.SGD","IE00BK4W5L77.USD","LU2106854487.HKD","LU0171276677.USD","LU1291159041.SGD","LU0823434740.USD","LU1868836757.USD","SG9999001176.USD","BK1588","LU0234570918.USD","LU0154236417.USD","LU0353189680.USD","LU0057025933.USD","LU0784384876.USD","LU0792757196.USD","LU0889566641.SGD","LU2168564222.USD","LU0985320562.USD","LU0162691827.USD","BK1574","BK4548","LU1035777561.USD","LU2213496289.HKD","HCM","LU2360032135.SGD","LU0348735423.USD","LU2488822045.USD","LU1015430645.USD","BK4566","LU1934455863.HKD","BMY","LU1645745479.HKD","LU1732799900.SGD","LU1487256676.USD","LU1226288170.HKD","BK1589","LU1267930573.SGD","LU2237438978.USD","00013","LU0225771236.USD","LU1226287875.USD","JDOC","SG9999014559.SGD","LU0738911758.USD","IHE","LU0348767384.USD","LU0211328371.USD","BK5011","FHLC","LU0323591593.USD","LU2399975544.HKD","BK4585","LU1807302812.USD","LU0987226296.USD","LU2355687059.USD","LU1831875114.USD","LU0077335932.USD","NVOH","LU1228905037.USD","LU1868836914.USD","GLAM","SGXZ57979304.SGD","LU0314109678.HKD","LU0345770308.USD","LU0114720955.EUR","LU0385154629.USD","BBH","IE00B1XK9C88.USD","LU1064131003.USD","01093","IE000M9KFDE8.USD","LU0784385840.USD","RXL","SG9999015341.SGD","LU1839511570.USD","LU0354030511.USD","BK4533","BK0196","IE00BFSS8Q28.SGD","LU1551013425.SGD","LU3187612489.SGD","LU0097036916.USD","LU1061106388.HKD","ELIL","LU1152091754.HKD","LU1979441026.SGD","IE00BWXC8680.SGD","LU0310799852.SGD","LU1400636491.USD","LU0965509283.SGD","LU0889565916.HKD","LU1301847155.USD","LU1261432733.SGD","LU0128525689.USD","LU0256863902.USD","LU0310800965.SGD","LU1323610961.USD","LU0106261372.USD","LU1153584641.USD","03165","LU2111349929.HKD","LU1069347547.HKD","LU0455707207.USD","LU1267930227.SGD","BK0188","LU0648001328.SGD","LU2552382058.USD","LU1152091168.USD","LU0326950275.SGD","LU2133065610.SGD","LU2097828474.EUR","IE00BPRC5H50.USD","LU1074936037.SGD","LU2646069778.SGD","LU0965508806.USD","IE00B4JS1V06.HKD","LU0969580561.USD","SG9999001176.SGD","LU0348825331.USD","LU1883839398.USD","LU1244550494.USD","IE00B3PB1722.GBP","LU1046248800.SGD","LU1941712264.USD","LU2242644610.SGD","IE00B3M56506.USD","LU0208291251.USD","LU0971552830.HKD","LU0511384066.AUD","LU1116320737.USD","LU1127390331.HKD","LU0029864427.USD","LU1923622614.USD","LU0237698245.USD","LU1309081286.SGD","BK4581","LU1430594728.SGD","SG9999014906.USD","LU2129689605.HKD","LU0882574139.USD","LU2028103732.USD","BK1587","IE00B031HY20.USD","LU2456880835.USD","IE00BBT3K403.USD","MEDX","BK0028","LU0820561909.HKD","LU1232071149.USD","LU1988902786.USD","LU2236285917.USD","LU1496350502.SGD","IE0009355771.USD","LU0069063385.USD","LU0708994859.HKD","LU2476274308.USD","LU2580892789.USD","LU0310800379.SGD","LU0238689110.USD","LU0964806797.USD","LU2265009873.SGD","IE00B2B36J28.USD","BK4578","IE00BFSS7M15.SGD","SG9999014898.SGD","LU0316494557.USD","LU0949170426.SGD","LU1699723380.USD","LU2129689431.USD","BK4599","IE00BZ08YS42.EUR","LU0786609619.USD","LU0965509101.SGD","LLYX","LU2495084118.USD","BK4516","LU0942090050.USD","GB00BDT5M118.USD","SG9999018857.SGD","LU1170363599.USD","LU2125909247.SGD","LU1104425308.USD","LU1983299246.USD","CURE","600276","LU2539964713.USD","IE0001KFT4U8.USD","LU0949170772.SGD","IE00B5MMRT66.SGD","LU1032466523.USD","LU0820561818.USD","LU0553294199.USD","LU2360106947.USD","SGXZ81514606.USD","LU1019634622.SGD","LU0963555726.SGD","WDNA","LU2237443465.HKD","LU0011850046.USD","LU1863844749.USD","IE000SO60NU8.SGD","SG9999001440.SGD","IE000WAW04H5.SGD","LU0689472784.USD","LU0634319403.HKD","BK0012","SG9999011175.SGD","IE0000B7K699.USD","LU0047473722.SGD","LU0501845795.SGD","LU2097828805.USD","BK4550","IE00BDGV0183.EUR","LU1046234339.USD","LU0096364046.USD","LU2023250504.SGD","IE00BKVL7J92.USD","THNR","IE00BVYPNV92.GBP","GSK.UK","09926","IE00B7KXQ091.USD","LU0198837287.USD","LU0545039389.USD","LU0109981661.USD","LU1670756490.USD","LU1820825898.SGD","LU0496365809.HKD","LU1267930730.SGD","MRK","LU2237443978.SGD","LU1066051811.HKD","LU0353189763.USD","LU0960981461.USD","LU1093756168.USD","LU2242646821.SGD","LU0607220059.USD","GDOC","LU0912757837.SGD","LU1993786604.SGD","LU1670710588.SGD","LU0211326839.USD","IE00B4R5TH58.HKD","LU0109394709.USD","LU0784383803.USD","LU2347655073.USD","LU0158827948.USD","LU0432979614.USD","TBXU","BK4592","LU0072461881.USD","LU0124676726.USD","LU1355424745.HKD","LU1934455277.USD","IE00BKPKM429.USD","LU1997245094.SGD","LU1863844665.USD","LU0964807845.USD","HK0000165453.HKD","LU1814569148.SGD","IYH","IE00BJJMRX11.SGD","LU2168564495.EUR","LU2596442595.SGD","LU2168563687.JPY","LU2237443549.SGD","LU0499090636.EUR","RHHBY","LU0211331839.USD","LU0072913022.USD","SGXZ31699556.SGD","LU2125909593.SGD","IE00B543WZ88.USD","NVS","BK4568","LU0889565080.SGD","LU1003076772.USD","LU1226287792.SGD","IBB","LU2362540622.SGD","IE0034235071.USD","HRTS","LU0477156953.USD","LU0784385170.HKD","LU2746668974.SGD","SG9999018865.SGD","LU0256863811.USD","LU1084165304.USD","LU2089283258.USD","LLII","IE00BJJMRZ35.SGD","LU1481600234.SGD","SMMT","LU0348784397.USD","LU0997586515.USD","LU2468319806.SGD","BK1161","LU0061475181.USD","LU2756315318.SGD","LU2237443382.USD","LU1078025761.USD","LU0128525929.USD","LU1236620834.HKD","LU1868837300.USD","LU0321505439.SGD","LU1670627923.USD","LU1670710661.SGD","LU1880407132.USD","LU1929549753.HKD","LU0971552673.USD","LU1267930490.SGD","LU1585245621.USD","BK4588","LU0067412154.USD","LU1202635105.USD","01276","IE0005OL40V9.USD","LU0047473722.EUR","PAWZ","LU2462591350.SGD","LU1670711040.USD","IE00B1BXHZ80.USD","LU1228905540.USD","LU1732800096.USD","LU1794554557.SGD","LU2580892862.HKD","LU1917777945.USD","LU0070302665.USD","BK1583","LU2357305700.SGD","IE0002141913.USD","LU1051770623.HKD","LU1894683348.USD","LU2023251221.USD","LU2433249047.HKD","KURE","LU0348783233.USD","LU2091194634.USD","LU2750360997.AUD","BK4551","LU1066053197.SGD","LU1712237335.SGD","LU2087621335.USD","LU2097828557.USD","LU2108987350.USD","LU1974910355.USD","BK1515","LU1037948897.HKD","LU1880407215.USD","LU2293690082.USD","IE00BFXG1179.USD","LU0130102774.USD","LU0557290698.USD","LU0859254822.USD","LU1551013342.USD","LU1804176565.USD","SG9999013999.USD","LU0972486137.USD","LU1098665638.USD","LU0466842654.USD","LU1196032939.SGD","SG9999002232.USD","LU1302929846.USD","02096","LU0683600562.USD","LU0561508036.HKD","09995","IE00BQJZX424.USD","IE0008368742.USD","LU1496350171.SGD","LU0170899867.USD","LU0133085943.USD","LU0640476718.USD","IE0004445015.USD","LU1868837136.USD","LU1064131342.USD","SG9999015358.SGD","LU1064927863.SGD","BNTX","LU1057294990.SGD","LU0345770993.USD","LU1226288253.USD","LU0882574055.USD","LU0540923850.HKD","LU1623119135.USD","LU1969619763.USD","LU1066051498.USD","XLV","LU1236620750.USD","LU2361044865.SGD","IE000MB6IJN5.SGD","LU1720050803.USD","LU1066051225.USD","LU0708995401.HKD","LU0661504455.SGD","LU0456855351.SGD","01801","SG9999014880.SGD","LU2039709279.SGD","BK1593","SG9999014542.SGD","BK4535","LU2289578879.USD","IE0008369823.USD","LU0211326755.USD","LU0225284248.USD","LU0985481810.HKD","SG9999002224.SGD","SG9999014914.USD","LU1720051108.HKD","LU0203202063.USD","LU0130517989.USD","IE00B19Z3B42.SGD","LU1951186391.HKD","BK1521","LU1960683339.HKD","LU0203345920.USD","LU2148510915.USD","LU1146622755.USD","LU0348827113.USD","BK4139","LU2063271972.USD","LU0390134368.USD","LU0158827781.USD","LU1580142542.USD","IE00B3T34201.USD","IE00BK4W5M84.HKD","IE00BKPKM643.USD","LU0161305163.EUR","LU1267930813.SGD","LU0052756011.USD","LU0174119429.USD","BK0183","LU0320765646.SGD","LU2476274720.SGD","LU0203201768.USD","LU0405327148.USD","LU2750360641.GBP","LU1400636657.SGD","LU2242652126.USD","LU2896262040.SGD","LU0211327993.USD","LU1400636574.HKD","LU2778985437.USD","LU1829250122.USD","LU1781817850.SGD","LU2602419157.SGD","LU0321505868.SGD","LU1035773651.USD","LU1328615791.USD","LU1064130708.USD","LU0140636845.USD","LU2264538146.SGD","LU2114397693.USD","LU1003077747.HKD","LU2112291526.USD","LU0354030438.USD","LU0405327494.USD","IE0034235188.USD","BK4534","IE00BN29S564.USD","LU1226287529.USD","LU1670711123.USD","PFE","LU0348766576.USD","LU1280957306.USD","LU1894683264.USD","IE00B19Z3581.USD","SG9999004220.SGD","BK4532","SGXZ99366536.SGD","LU0109391861.USD","AGNG","LU2129689514.USD","LU0203347892.USD","PJP","LU1691799644.USD","LU1548497426.USD","LU0417516738.SGD","LU2361045086.USD","LU0006306889.USD","LU2471134523.USD","LU2125154778.USD","LU0320765059.SGD","LU0345777659.USD","LU0502904849.HKD","IE0004445239.USD","LU1153585028.USD","LU2328871848.SGD","BK0239","SG9999003800.SGD","LU1162221912.USD","LU0244354667.USD","LU1188198961.HKD","LU0976567544.SGD","LU0395794307.EUR","LU1997245177.USD","AZN.UK","LU0689626769.HKD","REGN","IE00BSNM7G36.USD","LU2125154935.USD","LU1720051017.SGD","LU0823399737.USD","LU1019632923.USD","LU0672654240.SGD","IE00BJJMRY28.SGD","LU1069344957.HKD","IE0002270589.USD","IE00BKDWB100.SGD","LU0266013472.USD","LU2087625088.SGD","IE00BWDBJ516.SGD","LU0997586432.USD","IE00BGHQF631.EUR","LU0058720904.USD","LU1023059063.AUD","SG9999015986.USD","LU0823434583.USD","LU1035775433.USD","LU0640478417.SGD","LU1989772840.SGD","IE000BZT7R73.USD","LU1481599808.USD","LU0861579265.USD","OZEM","LU0943347566.SGD","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672673718","title":"Wuxi Biologics (Cayman) Stock Slides 2.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2672673718","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672673718?lang=en_us&edition=fundamental","pubTime":"2026-10-02 16:32","pubTimestamp":1790929920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. slipped 2.7% to 54.55 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 2.6% to 23972.29.The stock's fall snapped a four-day winning streak.Wuxi Biologics  Inc. closed 3.5% short of its 52-week high of HK$56.50, which the company reached Sept. 30.Trading volume totaled 14.2 million shares, compared to the 50-day average of 35.0 million shares.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516422952.EUR","LU0456846285.SGD","BK1141","LU0029874905.USD","LU0052750758.USD","LU0326950275.SGD","LU0348827113.USD","LU0359202008.SGD","LU0516422440.USD","LU3063872942.SGD","IE00B0JY6N72.USD","LU0417516902.SGD","LU1242518931.SGD","LU1242518857.USD","LU0029874061.USD","LU0051755006.USD","LU0540923850.HKD","LU0348825331.USD","LU0039217434.USD","LU0516423091.SGD","BK1576","LU0856984785.SGD","LU1880383366.USD","LU0140636845.USD","LU0708995583.HKD","LU0572944931.SGD","LU0320764599.SGD","LU1720050803.USD","LU0128522744.USD","LU0417516738.SGD","LU0634319403.HKD","LU0979878070.USD","LU0823426480.USD","BK1610","LU0588546209.SGD","LU0348735423.USD","02269","LU0320764243.SGD","SG9999002463.SGD","LU0456827905.SGD","LU0823426308.USD","LU0561508036.HKD","LU0211977185.USD","LU0181495838.USD","LU0708995153.HKD","KURE","SG9999002562.SGD","LU0307460666.USD","LU0819121731.USD","LU0516422366.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672271376","title":"Akeso (SEHK:9926) Could Be 31% Undervalued As Phase III Trial Hits Key Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2672271376","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672271376?lang=en_us&edition=fundamental","pubTime":"2026-10-02 15:18","pubTimestamp":1790925532,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) just put fresh clinical data at the center of its story. The company reported that its Phase III HARMONi-GI1 trial for advanced biliary tract cancer hit key survival goals.\nAkeso shares have reacted quickly to the HARMONi-GI1 headlines, with a 1-day share price return of 2.26% and a 7-day move of 15.76%. This has built on a 30-day gain of 26.91%, yet the shares are still sitting on a year-to-date share price decline of 4.06% and a 1-year total shareholder return down 22.25%...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-could-be-31-undervalued-as-phase-iii-trial-hi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-could-be-31-undervalued-as-phase-iii-trial-hi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B5MMRT66.SGD","LU0348827113.USD","LU0348766576.USD","KURE","LU0348825331.USD","LU2476274308.USD","LU0348783233.USD","LU0417516738.SGD","LU1961090484.USD","BK1574","LU0417516571.SGD","LU0561508036.HKD","LU0348767384.USD","LU0540923850.HKD","LU0348784397.USD","LU2476274720.SGD","LU0634319403.HKD","LU2399975544.HKD","LU1794554557.SGD","LU1720050803.USD","LU2778985437.USD","LU0348735423.USD","09926","IE00BPRC5H50.USD","LU2488822045.USD","BK1161","IE00B543WZ88.USD","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672577917","title":"CSPC Pharmaceutical Group (SEHK:1093) Could Be 26% Undervalued Following Three Phase III Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2672577917","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672577917?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:26","pubTimestamp":1790853967,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (SEHK:1093) has just packed three late stage pipeline updates into one week, covering diabetes, lung cancer and breast cancer therapies and giving investors fresh clinical data to weigh.\nThe TG103, JMT101 and HB1801 updates have landed against a backdrop of building momentum in CSPC Pharmaceutical Group’s shares, with a 1-day share price return of 6.28%, a 90-day share price return of 33.38% and a 3-year total shareholder return of 109.87%. This suggests traders are...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-sehk1093-could-be-26-undervalued-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-sehk1093-could-be-26-undervalued-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1226287792.SGD","IE0008369823.USD","IE00BZ08YR35.GBP","LU0880133367.SGD","LU1152091754.HKD","IE00BZ08YS42.EUR","LU0315179316.USD","LU1226288170.HKD","LU0501845795.SGD","IE0008368742.USD","LU0140636845.USD","LU1328277881.USD","BK1191","IE00B031HY20.USD","LU1951186391.HKD","LU1226287875.USD","BK1521","LU1960683339.HKD","LU1226287529.USD","HK0000165453.HKD","KURE","LU1813983027.USD","LU1807302812.USD","IE00BZ08YT58.USD","SG9999004220.SGD","LU1226288253.USD","LU1152091168.USD","LU0072913022.USD","LU0326950275.SGD","BK1515","LU1008478684.HKD","LU0314109678.HKD","IE00B5MMRT66.SGD","DCF","IE00B543WZ88.USD","01093","LU0067412154.USD","LU2039709279.SGD","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672272734","title":"CSPC Reports Blood Sugar Reduction in Phase III Diabetes Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2672272734","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672272734?lang=en_us&edition=fundamental","pubTime":"2026-10-01 13:31","pubTimestamp":1790832718,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group  reported blood sugar reductions of up to 1.38 percentage points in a Phase III study of its efmedaglutide alfa injection in Chinese adults with type 2 diabetes.At Week 28, the 15-mg dose reduced HbA1c by 1.38 percentage points from baseline and was non-inferior to dulaglutide 1.5 mg, the company said in a Wednesday filing on the Hong Kong Exchange.The reduction was sustained through Week 52, with HbA1c falling 1.31 percentage points versus 1.25 percentage points for dulaglutide.CSPC said the safety profiles were generally similar across the treatment groups, with gastrointestinal events being the most common adverse events. No severe hypoglycemia was reported.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1521","IE00B031HY20.USD","BK1515","LU0501845795.SGD","LU1226288253.USD","BK1191","LU1993786604.SGD","IE0008368742.USD","SG9999004220.SGD","LU2039709279.SGD","LU0314109678.HKD","LU1226287792.SGD","IE0008369823.USD","LU0880133367.SGD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","LU0067412154.USD","IE00BZ08YS42.EUR","LU0326950275.SGD","LU1152091168.USD","IE00B5MMRT66.SGD","LU1008478684.HKD","LU1226287529.USD","LU1226288170.HKD","LU1960683339.HKD","LU1807302812.USD","LU0140636845.USD","LU1328277881.USD","IE00B543WZ88.USD","KURE","LU1152091754.HKD","HK0000165453.HKD","LU0072913022.USD","LU1226287875.USD","01093","LU1813983027.USD","LU0315179316.USD","LU1951186391.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672735924","title":"What IBI3003 Trial Progress Means For Innovent Biologics Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2672735924","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672735924?lang=en_us&edition=fundamental","pubTime":"2026-10-01 07:29","pubTimestamp":1790810983,"startTime":"0","endTime":"0","summary":"Innovent Biologics reported updated Phase 1 results for IBI3003, a trispecific antibody for relapsed or refractory multiple myeloma, with a recommended Phase 2 dose of 360 µg/kg and high response rates in heavily pretreated patients, alongside fresh regulatory progress including China approval of Jaypirca for CLL/SLL.\nThe combination of a broad, clinically active pipeline, EMA GMP certification for the Suzhou manufacturing site, and new China market access for Jaypirca highlights how...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/what-ibi3003-trial-progress-means-for-innovent-biologics-sto","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/what-ibi3003-trial-progress-means-for-innovent-biologics-sto","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0463099449.HKD","LU1188198961.HKD","LU2065732104.USD","LU2488822045.USD","LU1969619763.USD","KURE","BK1589","LU0244354667.USD","BK1161","LU2328871848.SGD","HK0000165453.HKD","LU0502904849.HKD","BK1583","LU2242644610.SGD","PRGS","LU2097828557.USD","01801","LU1831875114.USD","LU0455707207.USD","LU2097828474.EUR","LU2097828805.USD","LU0607220059.USD","BK4097","LU2097828631.EUR","LU0149534421.HKD","LU2097828714.EUR","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671051201","title":"Major Drugmakers Turn to China for Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2671051201","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671051201?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:17","pubTimestamp":1790770671,"startTime":"0","endTime":"0","summary":"FACTBOX-Major drugmakers turn to China for licensing dealsSept 30 (Reuters)-Novo NordiskNOVOb.COsaid on Tuesday it will pay up to$2.6 billionto Jiangsu Hengrui Pharmaceuticals600276.SSfor the rights t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL4N45M0T3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","01530","ABBV","JDOC","IXJ","LLYZ","LLYX","ILDR","PJP","GDOC","PAWZ","01801","THNR","IHE","VHT","KURE","MEDI","XLV","CURE","GSK.UK","FTXH","GLAM","MEDX","TMED","AGNG","CANC","FHLC","TRUH","LLII","BMED","RSHO","WDNA","ELIL","BNTX","ELIS","HRTS","MRK","MHIP","OZEM","09926","IYH","688331","CGNX","03692","00013","PPH","PFE","SMMT","RXL","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128085196","title":"CSPC Pharmaceutical (01093) Reveals Positive Phase III Results for Edaglutide Alfa Injection Combined with Metformin in Chinese Adults with Type 2 Diabetes at EASD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1128085196","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128085196?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:12","pubTimestamp":1790770347,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Limited (01093) has announced that the Group presented the positive results of a Phase III clinical study of its glucagon-like peptide-1 (GLP-1) receptor agonist, Edaglutide...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","LU0501845795.SGD","BK1191","LU1152091168.USD","LU1960683339.HKD","BK1521","LU0072913022.USD","IE00BZ08YT58.USD","LU1226287875.USD","IE00B031HY20.USD","LU1226287529.USD","LU0314109678.HKD","LU1008478684.HKD","LU1807302812.USD","LU1152091754.HKD","LU1993786604.SGD","IE0008369823.USD","IE00BZ08YS42.EUR","HK0000165453.HKD","IE0008368742.USD","LU0067412154.USD","KURE","LU0326950275.SGD","LU1226287792.SGD","LU0880133367.SGD","LU0140636845.USD","LU1226288253.USD","IE00B543WZ88.USD","BK1515","LU1951186391.HKD","SG9999004220.SGD","LU1328277881.USD","LU1813983027.USD","IE00BZ08YR35.GBP","LU0315179316.USD","01093","LU1226288170.HKD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672384227","title":"Should Phase III Cancer Trial Win Require Action From Akeso Stock Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672384227","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672384227?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:20","pubTimestamp":1790760033,"startTime":"0","endTime":"0","summary":"Akeso reported that its bispecific antibody ivonescimab achieved statistically significant and clinically meaningful superiority in overall survival, progression free survival, and objective response rate versus a durvalumab based regimen in the Phase III HARMONi-GI1 biliary tract cancer trial, with full data selected for a Presidential Symposium at ESMO 2026.\nThe cluster of nearly 30 ESMO 2026 presentations on ivonescimab, cadonilimab, and early ADC assets, plus fresh Phase I clearance for...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/should-phase-iii-cancer-trial-win-require-action-from-akeso","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/should-phase-iii-cancer-trial-win-require-action-from-akeso","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","LU0348767384.USD","LU0348783233.USD","IE00B543WZ88.USD","LU2778985437.USD","LU0540923850.HKD","LU2476274308.USD","IE00BPRC5H50.USD","LU0348735423.USD","LU1961090484.USD","KURE","LU0561508036.HKD","LU1794554557.SGD","LU0634319403.HKD","09926","LU1720050803.USD","LU2476274720.SGD","BK4211","LU0348827113.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","LU2488822045.USD","LU0417516902.SGD","LU0348766576.USD","LU2399975544.HKD","LU0348784397.USD","BK1161","LU0348825331.USD","LU0417516738.SGD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671274102","title":"CSPC Pharmaceutical Group Stock Rallies 6.3% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2671274102","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671274102?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:31","pubTimestamp":1790757060,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. advanced 6.3% to 10.07 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.4% to 24613.27.This was the stock's third consecutive day of gains.CSPC Pharmaceutical Group Ltd. closed 8.1% short of its 52-week high of HK$10.96, which the company achieved Jan. 30.The stock outperformed some of its competitors, as Sino Biopharmaceutical Ltd. rose 2.9%, SSY Group Ltd. rose 2.0%, and United Laboratories International Holdings Ltd. rose 4.2%.Trading volume totaled 158.1 million shares, compared to the 50-day average of 92.1 million shares.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1951186391.HKD","LU0501845795.SGD","IE00B5MMRT66.SGD","LU1152091754.HKD","LU0072913022.USD","BK1521","IE00BZ08YS42.EUR","LU2039709279.SGD","LU0067412154.USD","01093","IE00BZ08YR35.GBP","LU0140636845.USD","LU1993786604.SGD","IE00BZ08YT58.USD","91335","LU0326950275.SGD","BK1191","LU1226288170.HKD","LU1008478684.HKD","LU1813983027.USD","LU1328277881.USD","LU1226287875.USD","IE0008368742.USD","LU1226287792.SGD","LU1152091168.USD","LU1226287529.USD","BK1515","KURE","LU0880133367.SGD","LU1807302812.USD","IE00B031HY20.USD","LU0315179316.USD","LU1960683339.HKD","HK0000165453.HKD","LU0314109678.HKD","IE0008369823.USD","LU1226288253.USD","SG9999004220.SGD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671090274","title":"Wuxi Biologics (Cayman) Stock Rises 4.8% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2671090274","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671090274?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:30","pubTimestamp":1790757000,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. advanced 4.8% to 56.05 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.4% to 24613.27.This was the stock's fourth consecutive day of gains.Wuxi Biologics  Inc. hit a new 52-week high, surpassing its previous peak of HK$55.60, which the company reached Sept. 29.Trading volume totaled 43.7 million shares, compared to the 50-day average of 34.5 million shares.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423091.SGD","LU0128522744.USD","LU0588546209.SGD","LU1242518931.SGD","LU1880383366.USD","LU0540923850.HKD","LU0029874905.USD","BK1521","LU0456846285.SGD","LU0708995583.HKD","KURE","LU2039709279.SGD","LU0359202008.SGD","LU0572944931.SGD","LU0043850808.USD","LU0039217434.USD","LU1688375341.USD","LU1794554557.SGD","LU0516423174.USD","LU0417516902.SGD","LU0320764599.SGD","LU0320764243.SGD","LU3063872942.SGD","SG9999002463.SGD","BK1576","LU0634319403.HKD","LU0348735423.USD","LU1242518857.USD","LU0516422440.USD","IE00B0JY6N72.USD","BK1589","LU0140636845.USD","02269","LU0181495838.USD","LU0348827113.USD","LU0823426480.USD","LU0979878070.USD","LU0823426308.USD","LU0708995153.HKD","LU0819121731.USD","LU0856984785.SGD","SG9999002562.SGD","BK1610","BK1141","LU0307460666.USD","LU0029874061.USD","LU0128526141.USD","LU0456827905.SGD","LU0516422952.EUR","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103250819","title":"Goldman Sachs: Asian CDMOs Enter a Structural Growth Cycle, with Peptides, ADCs, Oligonucleotides, and AIDD as New Engines","url":"https://stock-news.laohu8.com/highlight/detail?id=1103250819","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103250819?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:14","pubTimestamp":1790756086,"startTime":"0","endTime":"0","summary":"From September 23 to 25, Goldman Sachs hosted its second Asian Healthcare CDMO (Contract Development and Manufacturing Organization) Day in Singapore, according to a report.The three-day event drew...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874061.USD","LU0106831901.USD","LU0051755006.USD","02359","LU1668664300.SGD","LU0326950275.SGD","LU0823426308.USD","IE0004091025.USD","IE0002270589.USD","LU0942090050.USD","BK1521","LU1688375341.USD","LU0456846285.SGD","LU0307460666.USD","LU2125910500.SGD","LU2237443978.SGD","03347","LU2039709279.SGD","LU0463099449.HKD","LU0327786744.USD","LU0043850808.USD","LU0516423091.SGD","LU0516422440.USD","LU1144417596.USD","LU1791807156.HKD","GS","BK1610","LU0244354667.USD","LU0456827905.SGD","BK4552","BK1576","LU2237438978.USD","LU0868494708.USD","LU0742534661.SGD","LU0417516902.SGD","LU0516423174.USD","LU0868494617.USD","BK1583","LU0359201612.USD","LU1242518857.USD","LU1804176565.USD","LU0572944931.SGD","IE00BSNM7G36.USD","LU2237443622.USD","BK1589","LU0359202008.SGD","LU1046422090.SGD","SG9999014674.SGD","LU0417516738.SGD","LU1868837300.USD","LU2045819591.USD","LU1868836757.USD","BK4585","LU0708995153.HKD","LU0320764243.SGD","LU0210536198.USD","LU0540923850.HKD","LU0634319403.HKD","LU1794554557.SGD","IE0004086264.USD","LU2237443895.HKD","LU2750360997.AUD","BK4504","SG9999002562.SGD","LU0251131958.USD","LU2750360641.GBP","BK4127","LU0181495838.USD","CDMO","LU0516422952.EUR","LU0819121731.USD","LU2471134952.CNY","LU0348766576.USD","LU0708995583.HKD","BK4139","KURE","LU0348825331.USD","LU0320764599.SGD","LU0345770993.USD","LU1894683348.USD","LU0588546209.SGD","LU0348767384.USD","LU0469268626.HKD","LU2471134796.USD","LU2242644610.SGD","BK4533","LU2237443465.HKD","LU1720050803.USD","LU0348735423.USD","LU1868836914.USD","SG9999002463.SGD","LU2488822045.USD","LU2237443382.USD","BK4516","IE00BFXG1179.USD","LU0979878070.USD","LU2896262040.SGD","LU1868837136.USD","LU1868836591.USD","BK1141","GSX","LU2265009873.SGD","LU0823426480.USD","LU0039217434.USD","LU0516422366.SGD","02269","BK4588","LU0348827113.USD","LU3063872942.SGD","LU0345770308.USD","02268","IE00B19Z3581.USD","LU2471134523.USD","IE0034235188.USD","IE00B0JY6N72.USD","LU0856984785.SGD","LU0096364046.USD","LU1894683264.USD","LU0052750758.USD","LU1880383366.USD","BK1191","IE00B19Z3B42.SGD","LU1188198961.HKD","03759","LU0128522744.USD","LU0140636845.USD","LU0128526141.USD","LU0061475181.USD","BK4550","LU2471134879.HKD","LU0251142724.SGD","LU0048573561.USD","LU0029874905.USD","06821","LU2237443549.SGD","LU0561508036.HKD","LU1242518931.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120927837","title":"Daiwa: Akeso's Global Partner Summit Secures AstraZeneca Investment, Boosting Ivonescimab's Global Peak Sales Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1120927837","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120927837?lang=en_us&edition=fundamental","pubTime":"2026-09-30 15:00","pubTimestamp":1790751620,"startTime":"0","endTime":"0","summary":"According to a research report from Daiwa, a \"Buy\" rating has been assigned to Akeso (09926).Akeso's global partner Summit (SMMT.US) announced on the evening of Monday (the 28th) US Eastern Time that...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0634319403.HKD","LU2778985437.USD","LU0348784397.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU2476274308.USD","LU0540923850.HKD","LU0561508036.HKD","09926","LU0348767384.USD","LU1720050803.USD","BK1574","LU0417516571.SGD","LU0348783233.USD","LU0348825331.USD","LU1961090484.USD","LU0417516902.SGD","LU1794554557.SGD","LU2488822045.USD","LU0348766576.USD","BK1161","IE00B543WZ88.USD","KURE","LU2476274720.SGD","LU0417516738.SGD","LU2399975544.HKD","LU0348735423.USD","LU0348827113.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172902077","title":"Nomura Assigns HK$138.29 Target Price and \"Buy\" Rating to Akeso","url":"https://stock-news.laohu8.com/highlight/detail?id=1172902077","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172902077?lang=en_us&edition=fundamental","pubTime":"2026-09-30 15:00","pubTimestamp":1790751617,"startTime":"0","endTime":"0","summary":"Nomura has issued a research report assigning a target price of HK$138.29 and a \"Buy\" rating to Akeso (09926).Nomura noted that before the Hong Kong stock market opened on September 29, Akeso and its...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","KURE","LU0348767384.USD","02157","BK1583","LU0634319403.HKD","LU0540923850.HKD","LU1720050803.USD","LU2476274720.SGD","LU2399975544.HKD","LU0561508036.HKD","IE00BPRC5H50.USD","EWH","LU0348735423.USD","BK1574","LU1794554557.SGD","LU1961090484.USD","LU0417516571.SGD","02162","LU0348825331.USD","LU0348766576.USD","IE00B543WZ88.USD","LU0417516902.SGD","LU2488822045.USD","LU0348784397.USD","LU2778985437.USD","BK1161","LU0417516738.SGD","LU0348783233.USD","IE00B5MMRT66.SGD","09926","BK1587","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128696299","title":"AI Drug Discovery Sector Heats Up: ChinaAMC Hang Seng Biotech (03069) Rises Over 4% Intraday, ChinaAMC Innovative Drugs (03525) Gains Over 3% in Afternoon Session","url":"https://stock-news.laohu8.com/highlight/detail?id=1128696299","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128696299?lang=en_us&edition=fundamental","pubTime":"2026-09-30 13:48","pubTimestamp":1790747302,"startTime":"0","endTime":"0","summary":"The AI drug discovery ETF extended its recent rally, with ChinaAMC Hang Seng Biotech (03069) climbing 3.58% to HK$16.8 as of press time, while ChinaAMC Innovative Drugs (03525) rose 2.95% to...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTHR","LU0359201612.USD","BK1191","HK0000320264.USD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU0880133367.SGD","LU1226287792.SGD","HK0000306685.HKD","LU1951186391.HKD","LU0140636845.USD","LU1993786604.SGD","LU1328277881.USD","BK1610","LU1226287875.USD","BK1583","BK1141","IE00BZ08YR35.GBP","LU0315179316.USD","BK1574","LU2543165471.USD","SG9999004220.SGD","BK4588","LU1960683339.HKD","CHAT","LU1807302812.USD","LU1813983027.USD","IE0008368742.USD","IE00B543WZ88.USD","KURE","01477","FDN","LU0072913022.USD","HK0000320223.HKD","LU1226287529.USD","03069","BK1515","BK4550","03525","IE00BZ08YS42.EUR","BK4585","LU0501845795.SGD","LU1152091168.USD","01276","AIPO","01548","LU0067412154.USD","01093","IE00BZ08YT58.USD","LU1008478684.HKD","LU0314109678.HKD","LU1023057109.AUD","QTOC","HK0000165453.HKD","LU0359201885.HKD","LU2039709279.SGD","LU1226288253.USD","BK1521","LU1152091754.HKD","AGIX","BK1576","IE0008369823.USD","ARTY","LU0359202008.SGD","IE00B031HY20.USD","HK0000306701.USD","LU1226288170.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170264265","title":"Hong Kong Pharma Stocks Defy Market Slump as AI Drug Discovery Leads; GenScript Surges Over 9% to New High, Hang Seng Healthcare ETF Huabao (159137) Underlying Index Rises Over 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1170264265","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170264265?lang=en_us&edition=fundamental","pubTime":"2026-09-30 10:30","pubTimestamp":1790735430,"startTime":"0","endTime":"0","summary":"On September 30, Hong Kong pharmaceutical stocks continued their independent rally, bucking the broader market trend. AI drug discovery led the charge, with XtalPi Holdings surging more than 4%,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["512170","CHAT","QTOC","AGIX","BK1191","BK1574","AIPO","ARTY","KURE","FLHK","01477","159718","159137","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101287526","title":"CSPC Pharma Shares Rise Nearly 6% on String of R&D Updates Spanning mRNA Cancer Vaccines and Recombinant Protein Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=1101287526","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101287526?lang=en_us&edition=fundamental","pubTime":"2026-09-30 10:30","pubTimestamp":1790735415,"startTime":"0","endTime":"0","summary":"CSPC Pharma (01093) rose nearly 6%, up 5.86% as of press time to HK$10.03, with turnover of HK$402 million.On the news front, between September 28 and 29, CSPC Pharma disclosed multiple R&D...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314109678.HKD","BK4585","LU0072913022.USD","LU1226287875.USD","BK1191","LU1152091168.USD","IE00BZ08YS42.EUR","01093","LU0140636845.USD","LU1951186391.HKD","LU1993786604.SGD","LU1807302812.USD","BK1515","IE0008368742.USD","LU1008478684.HKD","LU0067412154.USD","LU0880133367.SGD","LU0315179316.USD","LU1152091754.HKD","LU1960683339.HKD","BK1521","IE0008369823.USD","SG9999004220.SGD","LU1328277881.USD","IE00BZ08YR35.GBP","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","LU1813983027.USD","LU1226288253.USD","IE00B543WZ88.USD","LU2039709279.SGD","HK0000165453.HKD","KCAI","LU1226287792.SGD","LU1226288170.HKD","BK4588","159646","VXUS","KURE","LU1226287529.USD","IE00B031HY20.USD","LU0326950275.SGD","LU0501845795.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196637209","title":"Behind the Surge in BD Deals: Decoding the Differentiated Advantages of China's Innovative Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1196637209","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196637209?lang=en_us&edition=fundamental","pubTime":"2026-09-30 10:20","pubTimestamp":1790734834,"startTime":"0","endTime":"0","summary":"After years of development, China's innovative drug R&D now significantly outperforms overseas markets in both speed and cost, with its global competitiveness continuously rising.According to recent...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671221569","title":"CSPC Hits 5-Week High on US FDA's Nod on Herpes Zoster Vaccine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2671221569","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671221569?lang=en_us&edition=fundamental","pubTime":"2026-09-30 10:05","pubTimestamp":1790733901,"startTime":"0","endTime":"0","summary":"BUZZ-CSPC hits 5-week high on US FDA's nod on herpes zoster vaccine trial** Shares of CSPC Pharmaceutical Group1093.HKclimb 4.6% to HK$9.91, their highest level since August 26** Stock on track for the biggest one-day pct gain since September 21 in the third straight rising session** Top pct gainer in benchmark Hang Seng Index.HSI, which slips 0.4%** CSPC says its Recombinant Herpes Zoster Vaccine  for prevention of herpes zoster has obtained approval from the U.S. Food and Drug Administration to conduct relevant clinical trials in the US** CSPC also says Phase Ib clinical trial of JMT206 Injection for weight management in adult patients with overweight or obesity has been officially initiated at the first study centre in China** YTD, stock up 16%, Hang Seng Biotech Index.HSBIOup 15%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL1N45M019:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0072913022.USD","LU0315179316.USD","LU0501845795.SGD","LU1226288170.HKD","LU0067412154.USD","LU1226287875.USD","LU0326950275.SGD","LU1960683339.HKD","LU1993786604.SGD","IE00B5MMRT66.SGD","IE00B031HY20.USD","IE00BZ08YT58.USD","LU1226287792.SGD","01093","LU1152091754.HKD","LU1951186391.HKD","IE00BZ08YS42.EUR","IE0008369823.USD","LU0140636845.USD","HK0000165453.HKD","KURE","BK1515","LU1226287529.USD","LU0314109678.HKD","LU1152091168.USD","LU1813983027.USD","LU1008478684.HKD","SG9999004220.SGD","BK1191","LU1807302812.USD","IE00B543WZ88.USD","BK1521","IE0008368742.USD","LU2039709279.SGD","IE00BZ08YR35.GBP","LU1226288253.USD","LU1328277881.USD","LU0880133367.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173705860","title":"Hong Kong Stock Connect Innovative Drug Sector Defies Market Downturn as Top Pharmaceutical Firm Enters with US$2 Billion, Akeso Surges 15.54%, Hengrui Pharma Secures US$2.6 Billion BD Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1173705860","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173705860?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:20","pubTimestamp":1790680850,"startTime":"0","endTime":"0","summary":"On September 29, the Hong Kong stock market retreated, but innovative drugs led gains against the broader trend. The Hang Seng Stock Connect Innovative Drug ETF (520880) tracking index, with 100%...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2495084118.USD","LU0359202008.SGD","KURE","LU1781817850.SGD","IE00BPRC5H50.USD","LU0405327148.USD","LU1997245094.SGD","LU2097828557.USD","LU2543165471.USD","LU2778985437.USD","LU1820825898.SGD","LU1969619763.USD","LU2097828631.EUR","LU2328871848.SGD","LU0348784397.USD","LU0348825331.USD","LU2476274308.USD","06978","BK0028","LU1064131003.USD","LU1720050803.USD","IE00B543WZ88.USD","LU0405327494.USD","LU1064130708.USD","LU1961090484.USD","LU2097828474.EUR","LU2148510915.USD","MEDX","BK0196","09926","LU1328615791.USD","600276","LU0348783233.USD","BK0012","LU2488822045.USD","BK0188","LU0348767384.USD","LU0561508036.HKD","LU2580892789.USD","LNGR","LU2476274720.SGD","LU0348827113.USD","LU0634319403.HKD","LU2580892862.HKD","LU1580142542.USD","LU0359201885.HKD","LU0348766576.USD","159992","LU1655091616.SGD","LU0417516571.SGD","LU1023057109.AUD","LU0359201612.USD","LU0348735423.USD","LU2289578879.USD","LU0417516738.SGD","BK0183","IBBQ","IE00B5MMRT66.SGD","LU1997245177.USD","FLHK","LU1794554557.SGD","LU1255011170.USD","BK0239","LU2399975544.HKD","01276","BK1161","LU2097828714.EUR","BK1574","LU1146622755.USD","LU2097828805.USD","BK1191","LU0540923850.HKD","BK0060","LU0417516902.SGD","LU1997244956.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}